

CURRICULUM VITAE di:

Nominativo	Elisa Borghi
-------------------	--------------

Posizione accademica

Macrosettore:	06
Settore Concorsuale:	06/A3
Settore Scientifico Disciplinare:	MED/07
Qualifica:	PO
Anzianità nel ruolo:	1 anno
Sede Universitaria:	Università degli Studi di Milano
Struttura di afferenza (dipartimento o altro)	

Posizioni ricoperte precedentemente nel medesimo ateneo o in altri

Periodo	Fascia	Ateneo
2018-2021	PA	Università degli Studi di Milano
2006-2018	RU	Università degli Studi di Milano

Publicazioni Scientifiche

1. Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? *APMIS*. 2023 Mar 18. doi: 10.1111/apm.13310.
2. Bernardo G, Le Noci V, Ottaviano E, De Cecco L, Camisaschi C, Guglielmetti S, Di Modica M, Gargari G, Bianchi F, Indino S, Sartori P, Borghi E, Sommariva M, Tagliabue E, Triulzi T, Sfondrini L. Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness. *CANCER LETT*. 2023;555:216041. doi: 10.1016/j.canlet.2022.216041.
3. Rovito R, Bono V, Augello M, Tincati C, Mainoldi F, Beaudoin-Bussièrès G, Tauzin A, Bianchi S, Hadla M, Yellenki V, d'Arminio Monforte A, Casola S, Borghi E, Finzi A, Marchetti G. Association

- between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. *SCI REP.* 2022 Nov 16;12(1):19658. doi: 10.1038/s41598-022-23923-1.
4. Parodi C, Viganò I, Ottaviano E, Massa V, Borghi E, Beretta S, Di Francesco JC, Badioni V, Vignoli A; COV-EPI Study Group. Long-term analysis of the effects of COVID-19 in people with epilepsy: Results from a multicenter on-line survey across the pandemic waves. *EPILEPSY BEHAV.* 2022;135:108900. doi:10.1016/j.yebeh.2022.108900.
 5. Parodi C, Ottaviano E, Cocco N, Ancona S, Bianchi S, Massa V, Bartolotti R, Pezzoni B, Giuliani R, Borghi E, Ranieri R. Feasibility and acceptability of saliva-based testing for the screening of SARS-CoV-2 infection in prison. *FRONT PUBLIC HEALTH.* 2022;10:808030. doi:10.3389/fpubh.2022.808030
 6. Amendola A, Canuti M, Bianchi S, Kumar S, Fappani C, Gori M, Colzani D, Kosakovsky Pond SL, Miura S, Baggieri M, Marchi A, Borghi E, Zuccotti G, Raviglione MC, Magurano F, Tanzi E. Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy. *ENVIRON RES.* 2022;215(Pt 1):113979. doi:10.1016/j.envres.2022.113979.
 7. Di Profio E, Magenes VC, Fiore G, Agostinelli M, La Mendola A, Acunzo M, Francavilla R, Indrio F, Bosetti A, D'Auria E, Borghi E, Zuccotti G, Verduci E. Special Diets in Infants and Children and Impact on Gut Microbioma. *NUTRIENTS.* 2022;14(15):3198. doi: 10.3390/nu14153198.
 8. Dekkerová J, Černáková L, Kendra S, Borghi E, Ottaviano E, Willinger B, Bujdáková H. Farnesol Boosts the Antifungal Effect of Fluconazole and Modulates Resistance in *Candida auris* through Regulation of the *CDR1* and *ERG11*. *Genes. J FUNGI (Basel).* 2022;8(8):783. doi:10.3390/jof8080783.
 9. Panelli S, Calcaterra V, Verduci E, Comandatore F, Pelizzo G, Borghi E, Bandi C, Zuccotti G. Dysbiosis in Children With Neurological Impairment and Long-Term Enteral Nutrition. *FRONT NUTR.* 2022;9:895046. doi: 10.3389/fnut.2022.895046.
 10. Montanari C, Ceccarani C, Corsello A, Zuvadelli J, Ottaviano E, Dei Cas M, Banderali G, Zuccotti G, Borghi E, Verduci E. Glycomacropeptide Safety and Its Effect on Gut Microbiota in Patients with Phenylketonuria: A Pilot Study. *NUTRIENTS.* 2022;14(9):1883. doi: 10.3390/nu14091883.
 11. Castiglioni S, Di Fede E, Bernardelli C, Lettieri A, Parodi C, Grazioli P, Colombo EA, Ancona S, Milani D, Ottaviano E, Borghi E, Massa V, Ghelma F, Vignoli A, Lesma E, Gervasini C. KMT2A: Umbrella Gene for Multiple Diseases. *GENES (Basel).* 2022 Mar 15;13(3):514. doi: 10.3390/genes13030514.
 12. Canuti M, Bianchi S, Kolbl O, Pond SLK, Kumar S, Gori M, Fappani C, Colzani D, Borghi E, Zuccotti G, Raviglione MC, Tanzi E, Amendola A. Waiting for the truth: is reluctance in accepting an early origin hypothesis for SARS-CoV-2 delaying our understanding of viral emergence? *BMJ GLOB HEALTH.* 2022 Mar;7(3):e008386. doi: 10.1136/bmjgh-2021-008386.
 8. Lupori L, Cornuti S, Mazziotti R, Borghi E, Ottaviano E, Cas MD, Sagona G, Pizzorusso T, Tognini P. The gut microbiota of environmentally enriched mice regulates visual cortical plasticity. *Cell Rep.* 2022 Jan 11;38(2):110212. doi: 10.1016/j.celrep.2021.110212.
 9. Pivari F, Mingione A, Piazzini G, Ceccarani C, Ottaviano E, Brasacchio C, Dei Cas M, Vischi M, Cozzolino MG, Fogagnolo P, Riva A, Petrangolini G, Barrea L, Di Renzo L, Borghi E, Signorelli P, Paroni R, Soldati L. Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease. *NUTRIENTS.* 2022 Jan 5;14(1):231. doi: 10.3390/nu14010231.
 10. Ceccarani C, Viganò I, Ottaviano E, Redaelli MG, Severgnini M, Vignoli A, Borghi E. Is Gut Microbiota a Key Player in Epilepsy Onset? A Longitudinal Study in Drug-Naive Children. *FRONT CELL INFECT MICROBIOL.* 2021 Dec 3;11:749509. doi: 10.3389/fcimb.2021.749509.
 11. Ottaviano E, Borghi E, Giovati L, Falleni M, Tosi D, Magliani W, Morace G, Conti S, Ciociola T. Therapeutic Effect of an Antibody-Derived Peptide in a *Galleria mellonella* Model of Systemic Candidiasis. *INT J MOL SCI.* 2021 Oct 9;22(20):10904. doi: 10.3390/ijms222010904.
 12. Montanari C, Parolisi S, Borghi E, Putignani L, Bassanini G, Zuvadelli J, Bonfanti C, Tummolo A, Dionisi Vici C, Biasucci G, Burlina A, Carbone MT, Verduci E. Dysbiosis, Host Metabolism, and Non-communicable Diseases: Trialogue in the Inborn Errors of Metabolism. *Front Physiol.* 2021 Sep 6;12:716520. doi: 10.3389/fphys.2021.716520.

13. Barcellini L, Forlanini F, Sangiorgio A, Gambacorta G, Alberti L, Meta A, Gaia P, Amendola A, Tanzi E, Massa V, Borghi E, Fabiano V, Zuccotti GV. Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan? PLOS ONE. 2021 Sep 2;16(9):e0257046. doi: 10.1371/journal.pone.0257046.
14. Ottaviano E, Baron G, Fumagalli L, Leite J, Colombo EA, Artasensi A, Aldini G, Borghi E. Candida albicans Biofilm Inhibition by Two Vaccinium macrocarpon (Cranberry) Urinary Metabolites: 5-(3',4'-DihydroxyPhenyl)- γ -Valerolactone and 4-Hydroxybenzoic Acid. MICROORGANISMS. 2021 Jul 13;9(7):1492. doi: 10.3390/microorganisms9071492.
15. Ottaviano E, Parodi C, Borghi E, Massa V, Gervasini C, Centanni S, Zuccotti G; LollipopStudy Group, Bianchi S. Saliva detection of SARS-CoV-2 for mitigating company outbreaks: a surveillance experience, Milan, Italy, March 2021. EPIDEMIOL INFECT. 2021 Jul 30;149:e171. doi: 10.1017/S0950268821001473.
16. Junqueira JC, Mylonakis E, Borghi E. Galleria mellonella experimental model: advances and future directions. PATHOG DIS. 2021;79(5):ftab021. doi: 10.1093/femspd/ftab021
17. Di Fede E, Ottaviano E, Grazioli P, Ceccarani C, Galeone A, Parodi C, Colombo EA, Bassanini G, Fazio G, Severgnini M, Milani D, Verduci E, Vaccari T, Massa V, Borghi E, Gervasini C. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome. INT J MOL SCI. 2021;22(7):3621. doi: 10.3390/ijms22073621
18. Borghi E, Massa V, Carmagnola D, Dellavia C, Parodi C, Ottaviano E, Sangiorgio A, Barcellini L, Gambacorta G, Forlanini F; UNIMI SAL Study group, Zuccotti GV. Saliva sampling for chasing SARS-CoV-2: A Game-changing strategy. PHARMACOL RES. 2021 Mar;165:105380. doi: 10.1016/j.phrs.2020.105380.
19. Amendola A, Bianchi S, Gori M, Colzani D, Canuti M, Borghi E, Raviglione MC, Zuccotti GV, Tanzi E. Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. EMERG INFECT DIS. 2020 Dec 8;27(2). doi: 10.3201/eid2702.204632.
20. Verduci E, Carbone MT, Borghi E, Ottaviano E, Burlina A, Biasucci G. Nutrition, Microbiota and Role of Gut-Brain Axis in Subjects with Phenylketonuria (PKU): A Review. NUTRIENTS. 2020 Oct 29;12(11):3319. doi:10.3390/nu12113319.
21. Mingione A, Ottaviano E, Barcella M, Merelli I, Rosso L, Armeni T, Cirilli N, Ghidoni R, Borghi E, Signorelli P. Cystic Fibrosis Defective Response to Infection Involves Autophagy and Lipid Metabolism. CELLS. 2020 Aug 6;9(8):1845.
22. Ceccarani C, Bassanini G, Montanari C, Casiraghi MC, Ottaviano E, Morace G, Biasucci G, Paci S, Borghi E, Verduci E. Proteobacteria Overgrowth and Butyrate-Producing Taxa Depletion in the Gut Microbiota of Glycogen Storage Disease Type 1 Patients. METABOLITES. 2020 Mar 30;10(4):133.
23. Baron G, Altomare A, Regazzoni L, Fumagalli L, Artasensi A, Borghi E, Ottaviano E, Del Bo C, Riso P, Allegrini P, Petrangolini G, Morazzoni P, Riva A, Arnoldi L, Carini M, Aldini G. Profiling Vaccinium macrocarpon components and metabolites in human urine and the urine ex-vivo effect on Candida albicans adhesion and biofilm-formation. BIOCHEM PHARMACOL. 2020;173:113726. Doi: 10.1016/j.bcp.2019.113726
24. Borghi E, Vignoli A. Rett Syndrome and Other Neurodevelopmental Disorders Share Common Changes in Gut Microbial Community: A Descriptive Review. INT J MOL SCI. 2019;20(17):4160.doi: 10.3390/ijms20174160
25. Borghi E, Vignoli A, D'Agostino A. The contribution of microbiology to neuroscience: More complex than it seems? BEHAVIORAL AND BRAIN SCIENCES, vol. 42, 2019. Doi: <https://doi.org/10.1017/S0140525X18002844>
26. Mauri E, Naso D, Rossetti A, Borghi E, Ottaviano E, Griffini G, Masi M, Sacchetti A, Rossi F. Design of polymer-based antimicrobial hydrogels through physico-chemical transition. MATER SCI ENG C MATER BIOL APPL. 2019;103:109791.
27. Bassanini G, Ceccarani C, Borgo F, Severgnini M, Rovelli V, Morace G, Verduci E, Borghi E. Phenylketonuria Diet Promotes Shifts in Firmicutes Populations. FRONT CELL INFECT MICROBIOL. 2019 ;9:101.doi: 10.3389/fcimb.2019.00101
28. Marcos-Zambrano LJ, Bordallo-Cardona M, Borghi E, Falleni M, Tosi D, Muñoz P, Escribano P, Guinea J. Candida isolates causing candidemia show different degrees of virulence in Galleria mellonella. MED MYCOL. 2020;58(1):83-92.doi: 10.1093/mmy/myz027

29. Basilissi M, Tincati C, Merlini E, Ancona G, Borghi E, Borgo F, Barassi A, d'Arminio Monforte A, Marchetti G. Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. *PLOS ONE*. 2019;14(2):e0212075. doi: 10.1371/journal.pone.0212075
30. Nile C, Falleni M, Cirasola D, Alghamdi A, Anderson OF, Delaney C, Ramage G, Ottaviano E, Tosi D, Bulfamante G, Morace G, Borghi E. Repurposing Pilocarpine Hydrochloride for Treatment of *Candida albicans* Infections. *mSPHERE*. 2019;4(1):e00689-18. Doi: 10.1128/mSphere.00689-18
31. Dekkerová-Chupáčová J, Borghi E, Morace G, Bujdáková H. Up-Regulation of Antimicrobial Peptides Gallerimycin and Galiomicin in *Galleria mellonella* Infected with *Candida* Yeasts Displaying Different Virulence Traits. *MYCOPATHOLOGIA*. 2018;183(6):935-940. doi: 10.1007/s11046-018-0300-7
32. Borghi E, Massa V, Severgnini M, Fazio G, Avagliano L, Menegola E, Bulfamante GP, Morace G, Borgo F. Antenatal Microbial Colonization of Mammalian Gut. *REPROD SCI*. 2019;26(8):1045-1053. doi: 10.1177/1933719118804411
33. Diviccaro S, Giatti S, Borgo F, Barcella M, Borghi E, Trejo JL, Garcia-Segura LM, Melcangi RC. Treatment of male rats with finasteride, an inhibitor of 5 α -reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. *PSYCHONEUROENDOCRINOLOGY*. 2019;99:206-215. doi: 10.1016/j.psyneuen.2018.09.021
34. Verduci E, Moretti F, Bassanini G, Banderali G, Rovelli V, Casiraghi MC, Morace G, Borgo F, Borghi E. Phenylketonuric diet negatively impacts on butyrate production. *NUTR METAB CARDIOVASC DIS*. 2018;28(4):385-392. Doi: 10.1016/j.numecd.2018.01.004
35. Borgo F, Garbossa S, Riva A, Severgnini M, Luigiano C, Benetti A, Pontiroli AE, Morace G, Borghi E. Body Mass Index and Sex Affect Diverse Microbial Niches within the Gut. *Front Microbiol*. 2018;9:213. Doi: 10.3389/fmicb.2018.00213
36. Chupáčová J, Borghi E, Morace G, Los A, Bujdáková H. Anti-biofilm activity of antibody directed against surface antigen complement receptor 3-related protein-comparison of *Candida albicans* and *Candida dubliniensis*. *PATHOG DIS*. 2018;76(1). Doi: 10.1093/femspd/ftx127
37. Soldini S, Posteraro B, Vella A, De Carolis E, Borghi E, Falleni M, Losito AR, Maiuro G, Treçarichi EM, Sanguinetti M, Tumbarello M. Microbiological and clinical characteristics of biofilm-forming *Candida parapsilosis* isolates associated with fungaemia and their impact on mortality. *CLIN MICROBIOL INFECT*. 2017; pii: S1198-743X(17)30635-3. Doi: 10.1016/j.cmi.2017.11.005
38. Borgo F, Riva A, Benetti A, Casiraghi MC, Bertelli S, Garbossa S, Anselmetti S, Scarone S, Pontiroli AE, Morace G, Borghi E. Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. *PLOS ONE*. 2017;12(6):e0179739. Doi: 10.1371/journal.pone.0179739
39. Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for *Burkholderia cepacia* Complex Isolates from Cystic Fibrosis Patients. *ACS INFECT DIS*. 2017;3(7):502-511. Doi: 10.1021/acinfecdis.7b00020
40. Borghi E, Borgo F, Severgnini M, Savini MN, Casiraghi MC, Vignoli A. Rett Syndrome: A Focus on Gut Microbiota. *INT J MOL SCI*. 2017;18(2). pii: E344. Doi: 10.3390/ijms18020344
41. Mapelli ET, Cerri A, Borghi E, Palvarini M, Abramo P, Morace G, Menni S. A rare case of subcutaneous fusariosis in an immunocompetent patient. *G ITAL DERMATOL VENEREOL*. 2017;152(2):178-180.
42. Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, Berry D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. *ENVIRON MICROBIOL*. 2017;19(1):95-105. Doi: 10.1111/1462-2920.13463
43. Polonelli L, Ciociola T, Elviri L, Zanello PP, Giovati L, Arruda DC, Muñoz JE, Mortara RA, Morace G, Borghi E, Galati S, Marin O, Casoli C, Pilotti E, Ronzi P, Travassos LR, Magliani W, Conti S. A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents. *SCI REP*. 2016;6:35018. Doi: 10.1038/srep35018

44. Borgo F, Verduci E, Riva A, Lassandro C, Riva E, Morace G, Borghi E. Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study. *CHILD OBES*. 2017;13(1):78-84.doi: 10.1089/chi.2015.0194
45. Borghi E, Borgo F, Morace G. Fungal Biofilms: Update on Resistance. *ADV EXP MED BIOL*. 2016;931:37-47.
46. Tincati C, Merlini E, Braidotti P, Ancona G, Savi F, Tosi D, Borghi E, Callegari ML, Mangiavillano B, Barassi A, Bulfamante G, d'Arminio Monforte A, Romagnoli S, Chomont N, Marchetti G. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. *AIDS*. 2016;30(7):991-1003. Doi: 10.1097/QAD.0000000000001015
47. Padoan R, Poli P, Colombrita D, Borghi E, Timpano S, Berlucchi M. Acute *Scedosporium apiospermum* Endobronchial Infection in Cystic Fibrosis. *PEDIATR INFECT DIS J*. 2016;35(6):701-2. Doi: 10.1097/INF.0000000000001130
48. Caretti A, Torelli R, Perdoni F, Falleni M, Tosi D, Zulueta A, Casas J, Sanguinetti M, Ghidoni R, Borghi E, Signorelli P. Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against *A. fumigatus* airways infection. *BIOCHIM BIOPHYS ACTA*. 2016 Jun;1860(6):1089-97. Doi:
49. Lovero G, Borghi E, Balbino S, Cirasola D, De Giglio O, Perdoni F, Caggiano G, Morace G, Montagna MT. Molecular Identification and Echinocandin Susceptibility of *Candida parapsilosis* Complex Bloodstream Isolates in Italy, 2007-2014. *PLOS ONE*. 2016 Feb 26;11(2):e0150218.
50. Perdoni F, Signorelli P, Cirasola D, Caretti A, Galimberti V, Biggiogera M, Gasco P, Musicanti C, Morace G, Borghi E. Antifungal activity of Myriocin on clinically relevant *Aspergillus fumigatus* strains producing biofilm. *BMC MICROBIOL*. 2015;15(1):248.
51. Borghi E, Morace G, Borgo F, Rajendran R, Sherry L, Nile C, Ramage G. New strategic insights into managing fungal biofilms. *FRONT MICROBIOL*. 2015;6:1077.
52. Lassandro C, Banderali G, Radaelli G, Borghi E, Moretti F, Verduci E. Docosahexaenoic Acid Levels in Blood and Metabolic Syndrome in Obese Children: Is There a Link? *INT J MOL SCI*. 2015;21;16(8):19989-20000.
53. Rajendran R, Borghi E, Falleni M, Perdoni F, Tosi D, Lappin DF, O'Donnell L, Greetham D, Ramage G, Nile C. Acetylcholine Protects against *Candida albicans* Infection by Inhibiting Biofilm Formation and Promoting Hemocyte Function in a *Galleria mellonella* Infection Model. *EUKARYOTIC CELL*. 2015;14(8):834-44.
54. Riva A, Borghi E, Cirasola D, Colmegna S, Borgo F, Amato E, Pontello MM, Morace G. Methicillin-Resistant *Staphylococcus aureus* in Raw Milk: Prevalence, SCCmec Typing, Enterotoxin Characterization, and Antimicrobial Resistance Patterns. *J FOOD PROT*. 2015;78(6):1142-6.
55. Morace G., Perdoni F., Borghi E. Antifungal drug resistance in *Candida* species. *J GLOB ANTIMICROB RESIST* 2014;2 (4): 254-259.
56. Perdoni F, Falleni M, Tosi D, Cirasola D, Romagnoli S, Braidotti P, Clementi E, Bulfamante G, Borghi E. A histological procedure to study fungal infection in the wax moth *Galleria mellonella*. *EUR J HISTOCHEM* 2014;58: 2428.
57. Sherry L, Rajendran R, Lappin DF, Borghi E, Perdoni F, Falleni M, Tosi D, Smith K, Williams C, Jones B, Nile CJ, Ramage G. Biofilms formed by *Candida albicans* bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. *BMC MICROBIOL* 2014; 14: 1-28.
58. Orsi CF, Borghi E, Colombari B, Neglia RG, Quagliano D, Ardizzoni A, Morace G, Blasi E. Impact of *Candida albicans* hyphal wall protein 1 (HWP1) genotype on biofilm production and fungal susceptibility to microglial cells. *MICROB PATHOG*. 2014;69-70:20-7.
59. Montagna MT, Lovero G, Borghi E, Amato G, Andreoni S, Campion L, Lo Cascio G, Lombardi G, Luzzaro F, Manso E, Mussap M, Pecile P, Perin S, Tangorra E, Tronci M, Iatta R, Morace G. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. *EUR REV MED PHARMACOL SCI*. 2014;18(5):661-74.

60. Borghi E, Romagnoli S, Fuchs BB, Cirasola D, Perdoni F, Tosi D, Braidotti P, Bulfamante G, Morace G, Mylonakis E. Correlation between *Candida albicans* biofilm formation and invasion of the invertebrate host *Galleria mellonella*. *FUTURE MICROBIOL* 2014;9:163-73.
61. Borghi E, Andreoni S, Cirasola D, Ricucci V, Sciota R, Morace G. Antifungal resistance does not necessarily affect *Candida glabrata* fitness. *J CHEMOTHER* 2014;26(1):32-6.
62. Cirasola D, Sciota R, Vizzini L, Ricucci V, Morace G, Borghi E. Experimental biofilm-related *Candida* infections. *FUTURE MICROBIOL*. 2013;8(6):799-805.
63. Furi L, Ciusa ML, Knight D, Di Lorenzo V, Tocci N, Cirasola D, Aragonés L, Coelho JR, Freitas AT, Marchi E, Moce L, Visa P, Northwood JB, Viti C, Borghi E, Orefici G; BIOHYPO Consortium, Morrissey I, Oggioni MR. Evaluation of reduced susceptibility to quaternary ammonium compounds and bisbiguanides in clinical isolates and laboratory-generated mutants of *Staphylococcus aureus*. *ANTIMICROB AGENTS CHEMOTHER*. 2013;57(8):3488-97.
64. Oggioni MR, Ciusa ML, Furi L, Baldassarri L, Orefici G, Cirasola D, Martínez JL, Morrissey I, Borghi E. Lack of evidence for reduced fitness of clinical *Staphylococcus aureus* isolates with reduced susceptibility to triclosan. *ANTIMICROB AGENTS CHEMOTHER* 2012;56(11):6068-9.
65. Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. *INT J MICROBIOL* 2012; doi:10.1155/2012/349278 0.760
66. Ciceri P, Volpi E, Brenna I, Elli F, Borghi E, Brancaccio D, Cozzolino MG. The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification. *BIOCHEM BIOPHYS RES COMMUN* 2012; 418: 770-773.
67. Mapelli ET, Borghi E, Cerri A, Sciota R, Morace G, Menni S. Tinea corporis due to *Trichophyton rubrum* in a woman and Tinea capitis in her 15-day-old baby: molecular evidence of vertical transmission. *MYCOPATHOLOGIA* 2012; 173: 135-138.
68. Morace G, Borghi E, Iatta R, Amato G, Andreoni S, Brigante G, C. Farina C, Lo Cascio G, Lombardi G, Manso E, M. Mussap M, Pecile P, Rigoli R, Tangorra E, Valmarin M, Montagna MT. Antifungal susceptibility of invasive yeast isolates in Italy : the GISIA3 study in critically ill patients. *BMC INFECTIOUS DISEASES* 2011; 11:130.
69. Borghi E, R. Sciota, C. Biassoni, D. Cirasola, L. Cappelletti, L. Vizzini, P. Boracchi, G. Morace. Cell surface hydrophobicity: a predictor of biofilm production in *Candida* isolates? *J MED MICROBIOL* 2011;60:689-690.
70. Borghi E, Sciota R, Iatta R, Biassoni C, Montagna MT, Morace G. Characterization of *Candida parapsilosis* complex strains isolated from invasive fungal infections. *EUR J CLIN MICROBIOL INFECT DIS* 2011; 30:1437-1441.
71. Boschi D, Guglielmo S, Aiello S, Morace G, Borghi E, Fruttero R. Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy) pyrazole derivatives. *BIOORG MED CHEM LETT* 2011;21:3431-3434.
72. Borghi E, Morace G. Fungal infections in ICU patients: epidemiology and role of diagnostics. *MINERVA ANEST*. 2011; 76: 950-956.
73. Borghi E, Iatta R, Manca A, Montagna MT, Morace G. Case report: chronic airway colonization by *Scedosporium apiospermum* with a fatal outcome in a patient with cystic fibrosis. *MED MYCOL* 2010; 48: S108-S113.
74. Borghi E, Cainarca M, Sciota R, Biassoni C, Morace G. Molecular picture of community- and healthcare-associated methicillin-resistant *Staphylococcus aureus* circulating in a teaching hospital in Milan. *SCAN J INFECT DIS*, 2010; 42(11-12):873-878.
75. Borghi E, Iatta R, Sciota R, Biassoni C, Cuna T, Montagna MT, Morace G. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for antifungal susceptibility testing of invasive yeast isolates in Italy: the GISIA3 study. *J CLIN MICROBIOL*. 2010;48(9): 3153-3157.
76. Morace G, Borghi E, Iatta R, Montagna MT. Anidulafungin, a new echinocandin: in vitro activity. *DRUGS*. 2009;69 Suppl 1:91-4.
77. Iatta R, Napoli C, Borghi E, Montagna MT. Rare mycoses of the oral cavity: a literature epidemiologic review. *ORAL SURG ORAL MED ORAL PATHOL ORAL RADIOL ENDOD**. 2009;108(5):647-655.

78. Montagna MT, Caggiano G, Borghi E, Morace G. The role of the laboratory in the diagnosis of invasive candidiasis. *DRUGS*. 2009;69 Suppl 1:59-63.
79. Borghi E, La Francesca M, Gazzola L, Marchetti G, Zonato S, Foa P, d'Arminio Monforte A, Morace G. *Rhodococcus equi* infection in a patient with spinocellular carcinoma of unknown origin. *J MED MICROBIOL*. 2008; 57(11): 1431-1433.
80. Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. *AIDS* 2008;22(15):2035-2038.
81. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R, Calvo MG, Ferrante P. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. *J MED VIROL*. 2007;79(4):408-412.
82. Mancuso R, Delbue S, Borghi E, Pagani E, Calvo MG, Caputo D, Granieri E, Ferrante P. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. *J MED VIROL*. 2007;79(2):192-9.
83. Speciale L, Biffi R, Mancuso R, Borghi E, Mazziotti R, Ferrante P. Big endothelin-1 and interleukin-6 modulation in human microvascular endothelial cells after human herpesvirus 8 infection. *EXP BIOL MED* (Maywood). 2006;231(6):1171-5.
84. Delbue S, Pagani E, Guerini FR, Agliardi C, Mancuso R, Borghi E, Rossi F, Boldorini R, Veggiani C, Car PG, Ferrante P. Distribution, characterization and significance of polyomavirus genomic sequences in tumors of the brain and its covering. *J MED VIROL* 2005;77:447-454.
85. Borghi E, Pagani E, Mancuso R, Delbue S, Valli M, Mazziotti R, Giordano L, Micheli R, Ferrante P. Detection of herpesvirus-6A in a case of subacute cerebellitis and myoclonic dystonia. *J MED VIROL* 2005;75(3):427-429.
86. Delbue S, Sotgiu G, Fumagalli D, Valli M, Borghi E, Mancuso R, Marchioni E, Maserati R, Ferrante P. A case of a PML patient with four different JC virus TCR rearrangements in CSF, blood, serum and urine. *J NEUROVIROL* 2005; 11:51-57.
87. Pagani E, Delbue S, Mancuso R, Borghi E, Tarantini L, Ferrante P. Molecular analysis of JC virus genotypes circulating among the Italian healthy population. *J NEUROVIROL* 2003;9(5):559-566.
88. Boldorini R, Pagani E, Car PG, Omodeo-Zorini E, Borghi E, Tarantini L, Bellotti C, Ferrante P, Monga G. Molecular characterization of JCV virus strains detected in human brain tumors. *PATHOLOGY*. 2003;35:248-253.
89. Kim J, Woolridge S, Biffi R, Borghi E, Lassak A, Ferrante P, Amini S, Khalili K, Safak M. Members of the AP-1 family, c-Jun and c-Fos, functionally interact with JC virus early regulatory protein large T antigen. *J VIROL*. 2003;77(9):5241-5252.
90. Ferrante P, Delbue S, Pagani E, Mancuso R, Marzocchetti A, Borghi E, Maserati R, Bestetti A, Cinque P. Analysis of JC virus genotype distribution and transcriptional control region rearrangements in human immunodeficiency virus-positive progressive multifocal leukoencephalopathy patients with and without highly active antiretroviral treatment. *J NEUROVIROL* 2003; 9 Suppl 1:42-46.

Titoli ¹

- Responsabilità scientifica generale o di unità (work package, unità nazionale nei progetti europei o locale in quelli nazionali ecc.) per progetti di ricerca internazionali e nazionali ammessi al finanziamento sulla base di bandi competitivi che prevedano la revisione tra pari:
 - **2022/2025-** PNRR: D³ 4 Health- Digital Driven Diagnostics, prognostics and therapeutics for sustainable Health care- Unità UNIMI (PI Monica Miozzo) Budget: 5.600.000 Euro
 - **2021/2024-** HORIZON-HLTH-2021-CORONA-01- EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Immunological Surveillance- Unità UNIMI (PI Agostino Riva). Budget: 1.511.016 Euro
 - **2021/2022-** Telethon Spring Seed Grant 2021: "Characterization of the gut microbiota in Cdk5

¹ In via esemplificativa sono indicate alcune voci

- deficiency disorder patients" Co-PI. Budget: 49.854 Euro
 - **2019-2020** Principal investigator per lo studio "Set up a microbial platform for bacteria-based algorithms computation techniques" affidato da Bacteria Intelligence Limited, Budget: 7.780 Euro
 - **2019/2020** - LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Addressing the new mycological challenge: *Candida auris* resistance and environmental persistence". Principal Investigator. Budget: 5.570 Euro
 - **2018/2019** - LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Manipulating gut microbiota in the host model *Galleria mellonella*". Principal Investigator. Budget: 17.800 Euro
 - **2017/2018** - LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Counteracting *Candida albicans* biofilms using bacterial weapons". Principal Investigator. Budget: 7.014 Euro
 - **2017/2018** - Principal investigator per lo studio "Efficacy of *Vaccinium macrocarpon* (cranberry) extract in inhibiting *Candida albicans* adhesion" affidato da INDENA S.p.A. Budget: 10.500 Euro
 - **2016/2017**- LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Diet restriction in phenylketonuric children: Microbes' pros and cons". Principal Investigator. Budget: 5.250 Euro
 - **2015/2016** - LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Investigating new paradigms in the pathogenesis of *C. albicans* invasive infections using a *Galleria mellonella* model". Principal Investigator. Budget: 10.500 Euro
 - **2014/2015** - LINEA B, Università degli Studi di Milano, bando competitivo dipartimentale: "Studio della risposta immunitaria, cellulare ed umorale, dell'invertebrato *Galleria mellonella* dopo infezione con ceppi di *Candida albicans* con diversa propensione a formare biofilm". Principal Investigator. Budget: 8.850 Euro
 - **2013/2015** - Fondazione Fibrosi Cistica: "Sphingolipid targeting in inflammation and fungal infection". Grant numero: FFC #20/2013. Responsabile Unità di Ricerca, budget unità 25.000 Euro
 - **2013/2015** - Bando Giovani Ricercatori GR 2009- Ministero della Salute: "Study of the Causal Relationship between Intestinal Permeability, Microbial Translocation and T Lymphocyte Hyperactivation in HIV-Infected Patients with Poor Immunological Response in Course of Suppressive HAART", Grant numero: GR-2009-1592029. Responsabile Unità di Ricerca; budget unità 12.000 Euro
 - **2013/2014** – European Society of Clinical Microbiology and Infectious disease Research Grant: "Sphingolipid targeting in microbial infection and inflammation" Principal Investigator, 20.000 Euro
 - **2011** - Co-investigator per lo studio "Community-biofilm: effects on antimicrobial resistance" affidato da PFIZER ITALIA s.r.l. Codice accordo 14550 del 26/01/2011. Budget: 35.000 Euro
 - **2008** - Bando PUR 2006-2008: Epidemiologia molecolare di ceppi di *Staphylococcus aureus* meticillino-sensibili (MSSA) e meticillino-resistenti (MRSA) isolati da emocoltura. Grant: 2008-ATE-0693. Principal Investigator, 3.833,74 Euro
 - **2007** - Bando PUR 2006-2008: Messa a punto di un sistema in vitro per lo studio dell'interazione tra HHV-6 e *Cryptococcus neoformans* a livello del sistema nervoso centrale Grant: 2007-ATE-0298. Principal Investigator, 2.254,61 Euro
 - **2007** - Co-investigator per lo studio multicentrico "A multicenter in vitro study of the etiology of severe yeast infections in general and surgical intensive care units and the in vitro susceptibility to systemic antifungal drugs of isolates that cause them- GISIA 3-" affidato da PFIZER ITALIA s.r.l. Codice accordo 9393. Budget: 57.000 Euro
- Direzione o partecipazione a comitati di direzione di riviste Scopus/WOS o classificate da ANVUR, nonché di collane editoriali, enciclopedie e trattati di riconosciuto prestigio nel settore:
 - **2022-2023**- Guest editor di "The Eurobiofilms 2022 special issue" per la rivista Biofilm
 - **2020-2021** – Guest editor del Thematic Issue su *Galleria mellonella* per la rivista Pathogens and Disease
 - **2019** - Guest Editor for the Special Issue "Gut Microbiota and Malnutrition" in Nutrients (MDPI)
 - **Dal 2018 al 2021**- Editore Associato della rivista Journal de Mycologie Médicale
 - **Dal 2019 ad oggi** - Editore Associato della rivista BMC Microbiology
 - **Dal 2016 ad oggi** - Membro del Board scientifico del portale microbioma.it, co-coordinato dalla Società Italiana di Microbiologia
 - **Dal 2014 ad oggi** - Revisore per l'ESCMID degli abstract annualmente sottoposti al congresso ECCMID
 - **Dal 2014 ad oggi** - Revisore per l'ESCMID dei bandi competitivi "Young Research Grant"
 - **Dal 2013 ad oggi** - Revisore per numerose riviste internazionali tra cui: PLOS One, BMC Microbiology, Scientific Reports, Clinical Microbiology and Infection, Medical Mycology, Virulence, Frontiers in Microbiology, Microorganisms, Pathogens and Disease.

- Partecipazione al collegio dei docenti nell'ambito di dottorati di ricerca accreditati dal Ministero:
 - **Dal 2013**, docente del Collegio di Dottorato di Ricerca in Medicina Molecolare e Traslazionale, Università degli Studi di Milano
- Incarichi di insegnamento o di ricerca (fellowship) presso qualificati atenei e istituti di ricerca esteri o sovranazionali:
 - **2017**- Visiting Professor at Karaganda State Medical University
 - **2011**- Visiting Scientist at the Division of Infectious Diseases, Massachusetts General Hospital- Harvard Medical School. Chief of the Department: Eleftherios Mylonakis.
- partecipazione come relatore a convegni di carattere scientifico nazionali o internazionali:
 - **2023** - Invited speaker al convegno "NUTRIZIONE E DINTORNI NEL BAMBINO 2021" (Milano, Italia)
 - **2022**- Chair for the "The quest for reliable biofilm models – how to narrow the gap to clinical implementation?" educational workshop at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Lisbon, Portugal)
 - **2022**- Invited speaker for the "Integrated Lunch Symposium on self collection" sponsored by Copan at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Lisbon, Portugal)
 - **2022**- International Scientific Advisory Board member for the Eurobiofilms2022 (Mallorca, Spain)
 - **2022** - Invited speaker al convegno "NUTRIZIONE E DINTORNI NEL BAMBINO 2021" (Milano, Italia)
 - **2021** – Comitato scientifico e organizzatore del "Galleria mellonella Workshop", 16-17 Luglio 2021
 - **2021**- Invited speaker at the ASM Microbe 2021 WORKSHOP: "The mouse never lies" (Anaheim,CA, USA)
 - **2021**- Invited speaker al convegno "NUTRIZIONE E DINTORNI NEL BAMBINO 2021" (Milano, Italia)
 - **2020**- Invited speaker al convegno "NUTRIZIONE E DINTORNI NEL BAMBINO 2020" (Milano, Italia)
 - **2019**- Invited speaker at the EUROBIOPILMS 2019 WORKSHOP "Working with *in vivo* biofilm infection models" (Glasgow, UK)
 - **2019**- Comunicazione orale al "47° Congresso della Società Italiana di Microbiologia" (Roma, Italia)
 - **2019**- Chair for the "Mechanisms at play in biofilm-associated infections" session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Amsterdam, Netherlands)
 - **2018**- Invited speaker al "46° Congresso della Società Italiana di Microbiologia" (Palermo, Italia)
 - **2015**- Invited speaker al "3rd International Conference on Model Hosts 2015" (Creta, Grecia)
 - **2015**- Invited speaker al convegno "Milano Biofilm Meeting 2015 Implantables and Infection Control: a Promising Future? Biofilms and Bacteria, Host and Nutrition, Biomaterials and Implants" (Milano, Italia)
 - **2015**- Invited speaker al "43° Congresso della Società Italiana di Microbiologia" (Napoli, Italia)
 - **2014**- Invited speaker al convegno "Significance of Experimental Models for Studying Bacterial Meningitis and Sepsis", organizzato dall'ESCMID Meningitis Study Group (EMESG), (Siena, Italia)
 - **2014**- Invited speaker al convegno "MILANOPEDIATRIA 2014 Nutrizione Genetica Ambiente per l'educazione alla salute" (Milano, Italia)
 - **2014**- Invited speaker al convegno "3rd meeting of the ECMM/ISHAM working group on Fungal respiratory infections in Cystic Fibrosis" (Angers, Francia)
 - **2014**- Comunicazione orale al "ESCMID Study Group for Biofilms focused on biofilm-based healthcare-associated infections" (Roma, Italia)
 - **2014**- Comunicazione orale al "42° Congresso della Società Italiana di Microbiologia" (Torino, Italia)
 - **2013**- Invited speaker nella sessione RESEARCH HIGHLIGHTS al "41° Congresso della Società Italiana di Microbiologia" (Riccione, Italia)
 - **2013**- Invited speaker al convegno "Biofilm-Related Infections in Orthopedic and Trauma Surgery. International Collaborative Projects Ahead" (Milano, Italia)
 - **2013**- Comunicazione orale al "2nd Fungal Biofilms Meeting" (Glasgow, Regno Unito)
 - **2012**- Comunicazione orale al "XI Congresso della Federazione Italiana di Micologia Umana ed Animale" (Catania, Italia)
 - **2012**- Comunicazione orale al "18th International Congress of the International Society of Human and Animal Mycology (ISHAM)" (Berlino, Germania)
 - **2011**- Comunicazione orale al "39° Congresso della Società Italiana di Microbiologia" (Riccione, Italia)
 - **2011**- Comunicazione orale al "2nd European Congress on Microbial Biofilms – Basic and Clinical Aspects- EUROBIOPILM 2011" (Copenaghen, Danimarca)
 - **2011**- Comunicazione orale al "21st European Congress of Clinical Microbiology and Infectious

- Diseases (ECCMID) and 27th International Congress of Chemotherapy (ICC)" (Milano, Italia)
 - **2010-** Comunicazione orale al "X Congresso della Federazione Italiana di Micologia Umana e Animale" (Milano, Italia)
 - **2010-** Comunicazione orale al "38° Congresso della Società Italiana di Microbiologia" (Riccione, Italia)
 - **2009-** Comunicazione orale al "37° Congresso della Società Italiana di Microbiologia" (Torino, Italia)
- direzione o partecipazione a gruppi di ricerca, nazionali o internazionali, legati a università ovvero a qualificate istituzioni pubbliche o private:
 - **Dal 2020** – Membro del Centro di Ricerca Coordinato (CRC) EpiSoMi (Epidemiologia e Sorveglianza Molecolare delle Infezioni), Università degli Studi di Milano
 - **Dal 2019-** Educational officer del gruppo di studio "ESCMID Study Group for Biofilms - ESGB" della Società Europea di Microbiologia Clinica e Malattie Infettive (ESCMID)
 - **Dal 2019-** Membro del gruppo di studio "ESCMID ESCMID Study Group for host and microbiota interaction – ESGHAMI" della Società Europea di Microbiologia Clinica e Malattie Infettive (ESCMID)
 - **2017-2019-** Membro del comitato esecutivo del gruppo di studio "ESCMID Study Group for Biofilms - ESGB" della Società Europea di Microbiologia Clinica e Malattie Infettive (ESCMID)
 - **2014-2016-** Collaborazione scientifica con il gruppo del Prof. David Berry, University of Wien, per lo studio del ruolo del microbiota nell'obesità pediatrica
 - **Dal 2013-** Collaborazione scientifica con il gruppo del Prof. Gordon Ramage, University of Glasgow, per lo studio del ruolo del pathway colinergico anti-infiammatorio in infezioni sistemiche da *Candida albicans*
 - **Dal 2012-** Membro del gruppo di studio " ISHAM working group on Fungal respiratory infections in Cystic Fibrosis" della Società Internazionale di Micologia Umana e Animale
 - **Dal 2012-** Collaborazione scientifica con il gruppo del Prof. Maurizio Sanguinetti, Università Cattolica del Sacro Cuore di Roma per studi di nuove molecole ad azione antifungina
 - **Dal 2012-** Collaborazione scientifica con il gruppo del Prof. Luciano Polonelli e Prof.ssa Conti, Università degli Studi di Parma per lo studio dell'attività di peptidi antimicrobici su *Candida* spp.
 - **2011-2014-** Collaborazione scientifica con il gruppo del Prof. Marco Oggioni, Università di Siena (attualmente University of Leicester), su studi in vivo della sensibilità antimicrobica a biocidi di isolati clinici di *Staphylococcus aureus*

data

29/3/2023

(F.to)